U
HALO icon

UBS’s Halozyme HALO Stock Holding History

UBS’s Portfolio HALO Stock Details HALO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q3 		$1.22M Buy
133,766
+103,746
+346% +$988K ﹤0.01% 3397
2014
Q2 		$297K Buy
30,020
+17,965
+149% +$152K ﹤0.01% 4757
2014
Q1 		$153K Sell
12,055
-28,552
-70% -$424K ﹤0.01% 5499
2013
Q4 		$609K Buy
40,607
+27,907
+220% +$359K ﹤0.01% 4106
2013
Q3 		$140K Sell
12,700
-500
-4% -$4.17K ﹤0.01% 5619
2013
Q2 		$105K Buy
+13,200
New +$84.1K ﹤0.01% 5853

Other funds holding HALO

TS
Third Security Radford, Virginia $241M AUM 45.43% 1-Year Est. Return
IAM
Iridian Asset Management Westport, Connecticut $291M AUM 49.45% 1-Year Est. Return
BB
BB Biotech Schaffhausen, Switzerland $3.98B AUM 15.47% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SAM
Sectoral Asset Management Montreal, Quebec, Canada $121M AUM 73.47% 1-Year Est. Return
QF
QVT Financial New York $1.37B AUM 148.1% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
First Eagle Investment Management
First Eagle Investment Management New York $59B AUM 32.99% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

UBS's HALO Position: Q3 2014 in Review

UBS increased its Halozyme (HALO) stake by 346% in Q3 2014, buying an estimated $988K and bringing the position to 133,766 shares worth $1.22M. The position accounts for ﹤0.01% of the portfolio, ranked #3397.

UBS first reported a position in HALO in Q2 2013 and has held it in 6 quarters since. 121 funds tracked by Wall St. Rank hold HALO as of Q3 2014.

  • UBS held 133,766 shares of Halozyme worth $1.22M as of Q3 2014.
  • UBS bought 103,746 Halozyme shares in Q3 2014, an estimated $988K.
  • Halozyme made up ﹤0.01% of UBS's portfolio in Q3 2014, its #3397 holding.
  • UBS first reported a position in Halozyme in Q2 2013 and has held it in 6 quarters since.
  • 121 funds tracked by Wall St. Rank held Halozyme as of Q3 2014.

Based on UBS's 13F filing for Q3 2014, filed 12 Nov 2014.